SLC6A19-IN-4

Overview

SLC6A19-IN-4 is an allosteric-competitive and orally active B 0 AT1 inhibitor. SLC6A19-IN-4 inhibits both human and mouse B 0 AT1 with IC 50 values of 513 nM and 295 nM, respectively. SLC6A19-IN-4 exhibits excellent metabolic stability. SLC6A19-IN-4 significantly increases urinary phenylalanine (Phe) excretion and reduces plasma Phe levels through dual inhibition of B 0 AT1 in both the intestine (reducing absorption) and kidney (promoting excretion) in vivo. SLC6A19-IN-4 can be used for phenylketonuria (PKU) and other disorders involving SLC6 -family transporters research.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Amino Acid/Protein Metabolism | Products > Disease Areas > Phenylketonuria | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Amino acid Transporter

Product Information

• Catalog No.: HY-179581
• CAS No.: 2962069-39-0
• Molecular Formula: C16H16F3N3O3
• Molecular Weight: 355.31
• Purity: 99.55%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source